logo
Share SHARE
FONT-SIZE Plus   Neg

Pre-market Movers For Dec 7 (NFLX, ACRX, AMRN, AVGO, ZGNX)

Gainers:

AcelRx Pharmaceuticals, Inc. (ACRX) is rising 5 percent to $3.48. The company announced that it has priced its underwritten public offering of 12.5 million common shares at $3.31 per share.

Decliners:

Netflix, Inc. (NFLX) is down 0.36 percent to $85.86. Netflix disclosed that the company and its chief executive Reed Hastings each received a Wells Notice from SEC Staff about its intent to recommend to the SEC to bring a civil action for violations of fair disclosure related to statement he posted in Facebook in July about the 1 billion hour service usage.

Amarin Corporation plc (AMRN) is plunging 19 percent to $9.71. The company announced $100 million non-equity financing through a hybrid debt-like instrument. The company also noted that it is continuing to assess strategic options.

Avago Technologies Ltd. (AVGO) is falling over 2 percent to $34.30. The company announced the sale of 21.49 million ordinary shares by certain existing shareholders, including its President and chief executive and entities affiliated with certain directors.

Trading halt:

Trading in shares of Zogenix, Inc. (ZGNX) was halted.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Snack and beverage giant Pepsico Inc. reported Thursday significantly higher profit in its third quarter, reflecting the absence of last year's hefty Venezuelan impairment charges, despite weak revenues. Core earnings and revenues beat market estimates. Further, the company lifted its fiscal 2016 forecast on its performance and outlook for the fourth quarter. Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects.
comments powered by Disqus
Follow RTT